• Explore /
  • Poster
  • / A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.

A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.

Abstract Poster

Authors

Susanna Ulahannan

Susanna Varkey Ulahannan

University of Okahoma Health Sciences Center, Oklahoma City, OK

Susanna Varkey Ulahannan , John D. Powderly , Melissa Lynne Johnson , John C. Krauss , Manish Sharma , Diwakar Davar , Thomas Benjamin Karasic , Stephanie Gaillard , Yonchu Jenkins , Robert J. Stagg , Darrin Bomba , Nathan Standifer , Steven Smith , Peppi Prasit , Thomas Walter Dubensky Jr., Sam H. Whiting , Kyriakos P. Papadopoulos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT04344795

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3107)

DOI

10.1200/JCO.2023.41.16_suppl.3107

Abstract #

3107

Poster Bd #

305

Abstract Disclosures

Similar Posters

First Author: Diwakar Davar

Poster

2013 ASCO Annual Meeting

A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.

A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.

First Author: Joaquin Mateo

First Author: Iwona A. Lugowska

First Author: Andreea Varga